InMed Pharmaceuticals Inc.INM

InMed Pharmaceuticals Inc. (INM) just watched its planned merger with Mentari collapse because neither set of shareholders could be arsed to approve it-despite the board’s best efforts to frame the exercise as a ‘transformational leap forward.’ The SEC filing for the terminated deal bluntly states that InMed and Mentari failed ‘to obtain the required shareholder and stockholder approvals or to satisfy other closing conditions, including effectiveness,’ which is corporate-speak for ‘the champagne never popped and the merger is toast’ (source: INM 425, 2026-07-22, https://www.sec.gov/Archives/edgar/data/1728328/000121390026080423/ea0298834-425_inmed.htm).

While the merger drama played out, InMed’s balance sheet quietly told a different story: $5.2 million in cash, $41,625 in short-term investments, and a $3.0 million net loss for the quarter ending 31 March 2026. That’s enough to keep the lights on for a few more quarters, but not enough to fund a pipeline of late-stage clinical trials without a capital raise or a miracle cure (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1728328/000121390026080417/ea0298644-8k425_inmed.htm).

InMed describes itself as a biopharma company focused on the development of cannabinoid-based therapies for rare diseases, and its press releases insist its lead drug candidates are advancing toward IND and clinical trials. The evidence supplied, however, stops short of proving those candidates will work-or that the company can afford to run them. The gap between the polished platform story and the actual cash in the bank is now wider than a management desks’s credulity (source: InMed Pharmaceuticals News | Press Releases, https://www.inmedpharma.com/press-releases-2/).

InMed’s latest filings show revenue of $820,188 for the year ending 31 December 2025, a figure so small it reads like rounding error rather than a commercial launch. The company’s inventory balance stood at $947,898 at the same date, up $56,725 from the prior period, which suggests either cautious stockpiling or a pipeline so thin it can’t afford to run out of raw material (source: 10-Q, period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1728328/000121390026078891/xslF345X06/primary_doc.xml).

For investors trying to square the company’s narrative with its numbers, the tension is simple: InMed’s press releases trumpet progress toward IND and clinical trials, but the balance sheet tells a story of limited cash, growing losses, and a terminated merger that was supposed to fix everything. The only thing advancing faster than the rhetoric is the burn rate (source: InMed Pharmaceuticals News | Press Releases, https://www.inmedpharma.com/investors/press-releases/).

The company’s cash burn is evident in its operating cash flow: a negative $5.7 million for the quarter ending 31 March 2026, and shareholders’ equity of $6.9 million against liabilities of $2.2 million. The diluted loss per share was $0.73, and the weighted average diluted share count stood at 4.0 million shares-so dilution is already baked in, and further equity raises would dilute existing holders further (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1728328/000121390026080417/ea0298644-8k425_inmed.htm).